<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Scopus BioPharma Inc.

    Scopus BioPharma Inc.

    Scopus BioPharma develops small molecule therapeutics leveraging world-class exper...

    Scopus BioPharma develops small molecule therap...

    Filing Type:    RA
    RehabPath Inc.

    RehabPath Inc.

    We exist to make the first step in a family’s path to recovery the right step thro...

    We exist to make the first step in a family’s p...

    Amount Raised:    $26,162.00
    Fundraising Status:    EC
    Filing Type:    CF
    Phormed Inc

    Phormed Inc

    PhorMed is a clinical stage biopharmaceutical company located in Beverly Hills Cal...

    PhorMed is a clinical stage biopharmaceutical c...

    Amount Raised:    $128,700.00
    Fundraising Status:    EC
    Filing Type:    CF
    Royal Philips NV

    Royal Philips NV

    Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focuse...

    Royal Philips (NYSE: PHG, AEX: PHIA) is a leadi...

    Filing Type:    PU
    Allogene Therapeutics, Inc.

    Allogene Therapeutics, Inc.

    Allogene Therapeutics is a clinical stage biotechnology company pioneering the dev...

    Allogene Therapeutics is a clinical stage biote...

    Filing Type:    PU
    Myriad Genetics, Inc.

    Myriad Genetics, Inc.

    Myriad Genetics, Inc., is a leading precision medicine company dedicated to being ...

    Myriad Genetics, Inc., is a leading precision m...

    Filing Type:    PU
    Autolus Therapeutics plc

    Autolus Therapeutics plc

    Autolus is a clinical-stage, biopharmaceutical company, focused on the development...

    Autolus is a clinical-stage, biopharmaceutical ...

    Filing Type:    PU
    Equillium, Inc.

    Equillium, Inc.

    Equillium is a biotechnology company leveraging deep understanding of immunobiolog...

    Equillium is a biotechnology company leveraging...

    Filing Type:    PU
    Cytosorbents Corporation

    Cytosorbents Corporation

    CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immun...

    CytoSorbents Corporation (NASDAQ: CTSO) is a Ne...

    Filing Type:    PU
    Cue Biopharma, Inc.

    Cue Biopharma, Inc.

    Cue Biopharma is an innovative clinical stage immunotherapy company developing a n...

    Cue Biopharma is an innovative clinical stage i...

    Filing Type:    PU
    Curis, Inc.

    Curis, Inc.

    Curis is a biotechnology company focused on the development and commercialization ...

    Curis is a biotechnology company focused on the...

    Filing Type:    PU
    Adaptimmune Therapeutics PLC

    Adaptimmune Therapeutics PLC

    Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...

    Adaptimmune is a leader in TCR T-cell therapy, ...

    Filing Type:    PU
    ©2025 National Investor Network. All Rights Reserved.